Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of some unusual options trading activity on Friday. Stock traders acquired 8,964 call options on the company. This represents an increase of 308% compared to the average volume of 2,198 call options.

Institutional Trading of SELLAS Life Sciences Group

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC boosted its stake in SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock worth $99,000 after purchasing an additional 15,398 shares in the last quarter. Geode Capital Management LLC boosted its stake in SELLAS Life Sciences Group by 17.1% in the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after purchasing an additional 88,183 shares in the last quarter. Anson Funds Management LP acquired a new stake in SELLAS Life Sciences Group in the 3rd quarter worth approximately $992,000. XTX Topco Ltd acquired a new stake in SELLAS Life Sciences Group in the 3rd quarter worth approximately $78,000. Finally, State Street Corp boosted its stake in SELLAS Life Sciences Group by 30.2% in the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after purchasing an additional 40,500 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Performance

NASDAQ:SLS opened at $1.06 on Friday. The company’s 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.16. The stock has a market capitalization of $74.60 million, a P/E ratio of -1.54 and a beta of 2.41. SELLAS Life Sciences Group has a fifty-two week low of $0.50 and a fifty-two week high of $1.72.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.